ESC Premium Access

Panel discussion - SGLT2 inhibition, diabetes and CVD: where does this fit in CV risk management?

Topic: Diabetes management
Organised by Academic Medical Center Amsterdam. Dept Vascular Medicine and Physicians' Academy for Cardiovascular Education / Course Director: Prof John Kastelein / Supported by an unrestricted educational grant from Boehringer Ingelheim/Lilly

Congress Presentation

About the speakers

Doctor David Fitchett

St. Michael's Hospital, Toronto (Canada)
18 presentations
0 follower

Professor John J V McMurray

University of Glasgow, Glasgow (United Kingdom of Great Britain & Northern Ireland)
125 presentations
18 followers

4 more presentations in this session

Introduction - SGLT2 inhibition, diabetes and CVD: where does this fit in CV risk management?

Speaker: Doctor D. Fitchett (Toronto, CA)

Thumbnail

Challenging CV Risk in diabetes: ready for a new approach?

Speaker: Professor J. Deanfield (London, GB)

Thumbnail

SGLT-2 inhibitors in T2DM management: current position & future promise.

Speaker: Professor S. Inzucchi (New Haven, US)

Thumbnail

Heart failure & diabetes: SGLT2 inhibition, a paradigm shift?

Speaker: Professor J. McMurray (Glasgow, GB)

Thumbnail

Access the full session

SGLT2 inhibition, diabetes and CVD: where does this fit in CV risk management?

Speakers: Doctor D. Fitchett, Professor J. McMurray, Doctor D. Fitchett, Professor J. Deanfield, Professor S. Inzucchi...
Thumbnail

About the event

Image

ESC Congress 2016

27 August - 31 August 2016

Sessions Presentations

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb